Last reviewed 2026-05-13 · How we verify

Valtoco Nasal Product

Valtoco is a nasal spray formulation of diazepam that rapidly delivers the benzodiazepine to the systemic circulation to provide fast-acting seizure relief.

Valtoco is a nasal spray formulation of diazepam that rapidly delivers the benzodiazepine to the systemic circulation to provide fast-acting seizure relief. Used for Acute seizure clusters or breakthrough seizures in patients with epilepsy.

At a glance

Mechanism of action

Diazepam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor in the central nervous system, reducing neuronal excitability. The intranasal formulation allows rapid absorption through the nasal mucosa, achieving faster onset of action compared to oral or rectal routes, making it suitable for acute seizure management.

Approved indications

• Acute seizure clusters or breakthrough seizures in patients with epilepsy

Common side effects

• Somnolence
• Dizziness
• Headache
• Nasal irritation

Key clinical trials

• Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care (PHASE4)
• A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers (PHASE1)
• The Comparison of Different Administration Routes of Pediatric Premedication (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Valtoco Nasal Product CI brief — competitive landscape report
• Valtoco Nasal Product updates RSS · CI watch RSS
• University Hospitals Cleveland Medical Center portfolio CI